Cancer Immun Cancer Immunity

Copyright © 2013 by Barbara-ann Guinn known in acute myeloid leukemia (AML) at that time. We membrane antigen has induced significant levels of epitope-N--producing CD8+ T c al (20). Based on these cli Downloaded fro on May 17, 2016. © 2013 American Assoccancerimmunolres.aacrjournals.org m ell responses in an ongoing nical results, we wanted toCT antigens, provide attractive targets for cancer immunotherapy since their expression in normal tissue is highly restricted, being confined to germline tissues such as the testis (reviewed in (1, 2)). However, many CT genes characterized in solid tumours were found to have infrequent expression in myeloid leukemias (3-5). We used SEREX (reviewed in (6)) with minor modifications (7, 8) to immunoscreen a normal donor testis cDNA library with the aim of expanding the limited number of CT antigens with the FrC sequence reduced to a single domain (DOM), thereby decreasing the potential for peptide competition but retaining the MHC class II-restricted peptide p30 (19). The target epitope-specific sequence is then inserted at the C-terminus of FrC to aid processing and presentation. In multiple models (reviewed in (17)), this p.DOM-epitope design has been shown to induce high levels of epitope-specific CD8+ T cells. For patients with relapsed prostate cancer, a p.DOM-epitope design incorporating a peptide sequence from prostate-specific that a DNA vaccine encoding an altered PASD1 epitope can induce CTLs to target the natural peptide expressed by human tumour cells